# Combined biologic therapy targeting B cells and eosinophils in relapsing multiple sclerosis and severe asthma: a case report of ofatumumab and mepolizumab

## TL;DR

This case report shows that combining two biologic drugs can safely treat a patient with multiple sclerosis and severe asthma.

## Contribution

This is the first report of using ofatumumab and mepolizumab together in a patient with MS and severe eosinophilic asthma.

## Key findings

- The combination therapy was feasible and safe in a real-world clinical scenario.
- The patient had no adverse interactions between the two biologic treatments.

## Abstract

The management of multiple sclerosis (MS) in patients with significant comorbidities such as severe asthma presents unique therapeutic challenges. We report a case of successful combined biologic therapy with ofatumumab and mepolizumab in a patient with relapsing MS and pre-existing severe eosinophilic asthma, highlighting the feasibility and safety of dual biologic therapy. To our knowledge, this is the first report of concomitant use of ofatumumab and mepolizumab in a patient with MS and severe eosinophilic asthma, documenting the safety of a non-standard combination strategy in a real-world clinical scenario.